Quarterly ResultJul 30, 2026, 09:13 AM
Madrigal Q2 Product Revenue Jumps to $364.3M; Net Loss $57.9M
AI Summary
Madrigal Pharmaceuticals reported a substantial increase in product revenue for the second quarter and first half of 2026, driven by the commercialization of Rezdiffra. Quarterly product revenue reached $364.3 million, up from $212.8 million in the prior year, while the net loss widened to $57.9 million. The company also launched Rezdiffra in Germany in September 2025 and is evaluating it for broader MASH patient populations. Despite ongoing losses, Madrigal believes its current liquidity is sufficient for over a year.
Key Highlights
- Product revenue for Q2 2026 increased to $364.3 million from $212.8 million in Q2 2025.
- Product revenue for H1 2026 rose to $675.6 million from $350.1 million in H1 2025.
- Net loss for Q2 2026 was $57.9 million, compared to $42.3 million in Q2 2025.
- Net loss for H1 2026 was $152.3 million, compared to $115.5 million in H1 2025.
- Cash and cash equivalents increased to $292.7 million at June 30, 2026, from $198.7 million at Dec 31, 2025.
- Accumulated deficit reached $2,242.8 million as of June 30, 2026.
- Rezdiffra launched commercially in the U.S. in April 2024 and in Germany in September 2025.
Price Impact
More from MDGL